NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球心臟生物標誌物市場:按類型、用途、測試地點、到 2027 年的地區預測

Global Cardiac Biomarkers Market Research Report: Information by Type, by Application, by Location of Testing, and by Region -Forecast till 2027

出版商 Market Research Future 商品編碼 1022669
出版日期 內容資訊 英文 117 Pages
訂單完成後即時交付
價格
全球心臟生物標誌物市場:按類型、用途、測試地點、到 2027 年的地區預測 Global Cardiac Biomarkers Market Research Report: Information by Type, by Application, by Location of Testing, and by Region -Forecast till 2027
出版日期: 2021年06月01日內容資訊: 英文 117 Pages
簡介

市場動態

全球心臟生物標誌物市場在 2019 年最高達到 42.3602 億美元,預計 2020 年至 2027 年的複合年增長率將達到 16.36%。心臟生物標誌物主要用作證明不同心血管疾病的方法。心血管生物標誌物市場的主要驅動因素是心血管和生活方式疾病、心血管和生活方式疾病的流行、對疾病治療和研究的需求不斷增長、心血管生物標誌物的創新進展以及心臟。其中包括政府為提高對血管疾病的認識而採取的重大舉措。疾病。

本報告調查了全球心臟生物標誌物市場,按類型、應用、測試地點和區域提供了市場概況、趨勢和市場規模預測、市場增長和抑制因素分析以及冠狀病毒感染。它總結了影響(COVID-19)、競爭形勢、主要公司簡介等。

目錄

第 1 章執行摘要

第 2 章市場介紹

  • 調查範圍
  • 調查目的
  • 市場結構
  • 假設和限制

第 3 章調查方法

  • 數據挖掘
  • 二次調查
  • 初步調查
  • 主要受訪者的細分
  • 預測方法
  • 研究方法的市場規模預測
    • 自下而上的方法
    • 自上而下的方法
  • 數據三角剖分
  • 驗證

第 4 章市場動態

  • 概述
  • 促進因素
    • 心血管疾病和生活方式相關疾病的患病率增加
    • 對使用心臟生物標誌物的疾病特異性治療和研究的需求不斷增加
  • 抑制因素
    • 人們缺乏意識

第 5 章市場因素分析

  • 價值鏈分析
    • 研發設計
    • 製造
    • 分銷和銷售
    • 售後監控
  • 五力模型
  • 新型冠狀病毒感染(COVID-19)影響分析

第 6 章全球心臟生物標誌物市場:按類型

  • 概述
  • 肌鈣蛋白
  • 心肌肌酸激□ (CK-MB)
  • 肌紅蛋白
  • 心室利鈉□ (BNPS) 或 NT-PROBNP
  • 缺血修飾白蛋白 (IMA)
  • ALT/AST
  • 其他

第 7 章全球心臟生物標誌物市場:按應用

  • 概述
  • 心肌梗塞
  • 充血性心力衰竭
  • 急性冠脈症候群
  • 動脈粥樣硬化
  • 其他

第 8 章全球心臟生物標誌物市場:按檢查地點

  • 概述
  • POC 檢查
  • 實驗室測試

第 9 章全球心臟生物標誌物市場:按地區

  • 概述
  • 美洲
    • 北美
    • 拉丁美洲
  • 歐洲
    • 西歐
    • 東歐
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞
    • 其他
  • 中東/非洲
    • 中東
    • 非洲

第 10 章競爭形勢

  • 概述
  • 主要公司

第 11 章公司簡介

  • NOVARTIS AG
  • QUIDEL CORPORATION
  • ACS BIOMARKER B.V.
  • RANDOX LABORATORIES LTD
  • TRIVITRON HEALTHCARE
  • F. HOFFMAN LA ROCHE LTD
  • JOHNSON & JOHNSON SERVICES INC.
  • ABBOTT LABORATORIES
  • SIEMENS
  • THERMO FISHER SCIENTIFIC
  • BIO-RAD LABORATORIES, INC.
  • DANAHER CORPORATION
  • BIOMERIEUX SA

第 12 章附錄

  • 參考文獻
  • 相關報導
目錄
Product Code: MRFR/HC/7122-CR

Global Cardiac Biomarkers Market Research Report-Forecast till 2027

Market Dynamics

The global cardiac biomarkers market is expected to exhibit the highest CAGR of 16.36% during the review period of 2020 to 2027 owing to the largest value of USD 4236.02 Million in 2019. The overall cardiac biomarkers market is moderately isolated with rising competition, thing dispatches, rising aggregate affiliations, and other key decisions that are embraced to achieve useful usefulness. The vendors battle reliant upon cost, quality, optimal availability, and constancy of things promoted. The advancement of key market players is dependent upon financial circumstances, government support, and industry improvement. For example, COVID-19 has accepted a critical part in the addition of pursued cardiac biomarkers.

The cardiac biomarkers are primarily used as a coordinated demonstrative methodology for different cardiovascular illnesses. The key factors that drive the cardiac biomarkers market are the expanding commonness of cardiovascular illnesses and way of life infections, expanding pervasiveness of cardiovascular sicknesses and way of life illnesses, expansion sought after for sickness explicit therapy and exploration in which cardiac biomarkers are utilized, innovative headways in cardiac biomarkers, and great government drives to make mindfulness identified with cardiovascular sicknesses. Nonetheless, an absence of mindfulness among individuals is relied upon to hamper market development.

Segmental Overview

The global Cardiac biomarkers market has been classified into Type, application, and location of testing.

By Type segment the market has been classified into cardiac biomarker type - Creatine Kinase (CK-MB), Troponins T and I, myoglobin, BNPs, IMA, and others. By Application segment, the market is divided into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. In terms of the location of the testing, the segment is segmented as point-of-care testing and laboratory testing.

Regional Analysis

Geographically, the global cardiac biomarker market has been classified into the Americas, Europe, Asia-Pacific, and Middle East & Africa.

Americas is likely to dominate the global cardiac biomarker market owing to the increasing demand for cardiac testing, increasing prevalence of CVD rate, and the increasing awareness of cardiac diagnostics solutions. The regional market growth is attributed to the high rate of cardiovascular diseases & diabetes, product launch, and acquisition in this region.

The market in Asia-Pacific is rising at the fastest CAGR owing to modernization, increasing disposable incomes, and rising affordability for advanced cardiac treatments. The regional market growth is driven by the rising prevalence of cardiovascular diseases, COPD, and diabetes.

Major Players

The key market players in the global cardiac biomarkers market include Novartis AG (Switzerland), Quidel Corporation (US), Trivitron Healthcare (India), F. Hoffman La Roche Ltd (Switzerland), Johnson & Johnson Services Inc. (US), Abbott Laboratories (US), Siemens (Germany), Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories, Inc (US), Danaher Corporation (US), ACS Biomarker B.V (Netherlands), Randox Laboratories Ltd (UK), and Biomerieux SA (France).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 14

2 MARKET INTRODUCTION 15

  • 2.1 SCOPE OF THE STUDY 15
  • 2.2 RESEARCH OBJECTIVE 15
  • 2.3 MARKET STRUCTURE 15
  • 2.4 ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY 17

  • 3.1 DATA MINING 17
  • 3.2 SECONDARY RESEARCH 18
  • 3.3 PRIMARY RESEARCH 19
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20
  • 3.5 FORECASTING TECHNIQUES 20
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
    • 3.6.1 BOTTOM-UP APPROACH 22
    • 3.6.2 TOP-DOWN APPROACH 22
  • 3.7 DATA TRIANGULATION 23
  • 3.8 VALIDATION 23

4 MARKET DYNAMICS 24

  • 4.1 OVERVIEW 24
  • 4.2 DRIVERS 24
    • 4.2.1 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASE AND LIFESTYLE RELATED DISEASES 24
    • 4.2.2 INCREASE IN DEMAND FOR DISEASE-SPECIFIC TREATMENT & RESEARCH IN WHICH CARDIAC BIOMARKERS ARE USED 25
  • 4.3 RESTRAINTS 26
    • 4.3.1 LACK OF AWARENESS AMONG PEOPLE 26

5 MARKET FACTOR ANALYSIS 27

  • 5.1 VALUE CHAIN ANALYSIS 27
    • 5.1.1 R&D AND DESIGNING 28
    • 5.1.2 MANUFACTURING 28
    • 5.1.3 DISTRIBUTION & SALES 28
    • 5.1.4 POST-SALES MONITORING 28
  • 5.2 PORTER'S FIVE FORCES MODEL 29
    • 5.2.1 BARGAINING POWER OF SUPPLIERS 30
    • 5.2.2 BARGAINING POWER OF BUYERS 30
    • 5.2.3 THREAT OF NEW ENTRANTS 30
    • 5.2.4 THREAT OF SUBSTITUTES 30
    • 5.2.5 INTENSITY OF RIVALRY 30
  • 5.3 COVID-19 IMPACT ANALYSIS 31

6 GLOBAL CARDIAC BIOMARKERS MARKET, BY TYPE 32

  • 6.1 OVERVIEW 32
  • 6.2 TROPONINS (T AND I) 33
  • 6.3 MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB) 34
  • 6.4 MYOGLOBIN 34
  • 6.5 BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP 35
  • 6.6 ISCHEMIA MODIFIED ALBUMIN (IMA) 35
  • 6.7 ALT/AST 36
  • 6.8 OTHERS 36

7 GLOBAL CARDIAC BIOMARKERS MARKET, BY APPLICATION 37

  • 7.1 OVERVIEW 37
  • 7.2 MYOCARDIAL INFARCTION 38
  • 7.3 CONGESTIVE HEART FAILURE 39
  • 7.4 ACUTE CORONARY SYNDROME 39
  • 7.5 ATHEROSCLEROSIS 40
  • 7.6 OTHERS 40

8 GLOBAL CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING 41

  • 8.1 OVERVIEW 41
  • 8.2 POINT OF CARE TESTING 42
  • 8.3 LABORATORY TESTING 42

9 GLOBAL CARDIAC BIOMARKERS MARKET, BY REGION 43

  • 9.1 OVERVIEW 43
  • 9.2 AMERICAS 45
    • 9.2.1 NORTH AMERICA 47
      • 9.2.1.1 US 49
      • 9.2.1.2 CANADA 51
    • 9.2.2 LATIN AMERICA 52
  • 9.3 EUROPE 53
    • 9.3.1 WESTERN EUROPE 55
      • 9.3.1.1 GERMANY 57
      • 9.3.1.2 UK 58
      • 9.3.1.3 FRANCE 59
      • 9.3.1.4 ITALY 60
      • 9.3.1.5 SPAIN 61
      • 9.3.1.6 REST OF WESTERN EUROPE 62
    • 9.3.2 EASTERN EUROPE 63
  • 9.4 ASIA-PACIFIC 64
    • 9.4.1 CHINA 66
    • 9.4.2 INDIA 67
    • 9.4.3 JAPAN 68
    • 9.4.4 SOUTH KOREA 69
    • 9.4.5 AUSTRALIA 70
    • 9.4.6 REST OF ASIA-PACIFIC 71
  • 9.5 MIDDLE EAST & AFRICA 72
    • 9.5.1 MIDDLE EAST 74
    • 9.5.2 AFRICA 75

10 COMPETITIVE LANDSCAPE 76

  • 10.1 OVERVIEW 76
  • 10.2 MAJOR PLAYERS IN THE GLOBAL CARDIAC BIOMARKERS MARKET 77

11 COMPANY PROFILES 78

  • 11.1 NOVARTIS AG 78
    • 11.1.1 COMPANY OVERVIEW 78
    • 11.1.2 FINANCIAL OVERVIEW 79
    • 11.1.3 PRODUCTS/SERVICES OFFERED 79
    • 11.1.4 KEY DEVELOPMENTS 80
    • 11.1.5 SWOT ANALYSIS 80
    • 11.1.6 KEY STRATEGIES 80
  • 11.2 QUIDEL CORPORATION 81
    • 11.2.1 COMPANY OVERVIEW 81
    • 11.2.2 FINANCIAL OVERVIEW 82
    • 11.2.3 PRODUCTS/SERVICES OFFERED 82
    • 11.2.4 KEY DEVELOPMENTS 82
    • 11.2.5 SWOT ANALYSIS 83
    • 11.2.6 KEY STRATEGIES 83
  • 11.3 ACS BIOMARKER B.V. 84
    • 11.3.1 COMPANY OVERVIEW 84
    • 11.3.2 FINANCIAL OVERVIEW 84
    • 11.3.3 PRODUCTS/SERVICES OFFERED 84
    • 11.3.4 KEY DEVELOPMENTS 84
    • 11.3.5 SWOT ANALYSIS 85
    • 11.3.6 KEY STRATEGIES 85
  • 11.4 RANDOX LABORATORIES LTD 86
    • 11.4.1 COMPANY OVERVIEW 86
    • 11.4.2 FINANCIAL OVERVIEW 86
    • 11.4.3 PRODUCTS/SERVICES OFFERED 86
    • 11.4.4 KEY DEVELOPMENTS 86
    • 11.4.5 SWOT ANALYSIS 87
    • 11.4.6 KEY STRATEGIES 87
  • 11.5 TRIVITRON HEALTHCARE 88
    • 11.5.1 COMPANY OVERVIEW 88
    • 11.5.2 FINANCIAL OVERVIEW 88
    • 11.5.3 PRODUCTS/SERVICES OFFERED 88
    • 11.5.4 KEY DEVELOPMENTS 88
    • 11.5.5 SWOT ANALYSIS 89
    • 11.5.6 KEY STRATEGIES 89
  • 11.6 F. HOFFMAN LA ROCHE LTD 90
    • 11.6.1 COMPANY OVERVIEW 90
    • 11.6.2 FINANCIAL OVERVIEW 91
    • 11.6.3 PRODUCTS/SERVICES OFFERED 92
    • 11.6.4 KEY DEVELOPMENTS 92
    • 11.6.5 SWOT ANALYSIS 92
    • 11.6.6 KEY STRATEGIES 93
  • 11.7 JOHNSON & JOHNSON SERVICES INC. 94
    • 11.7.1 COMPANY OVERVIEW 94
    • 11.7.2 FINANCIAL OVERVIEW 95
    • 11.7.3 PRODUCTS/SERVICES OFFERED 95
    • 11.7.4 KEY DEVELOPMENTS 96
    • 11.7.5 SWOT ANALYSIS 96
    • 11.7.6 KEY STRATEGIES 96
  • 11.8 ABBOTT LABORATORIES 97
    • 11.8.1 COMPANY OVERVIEW 97
    • 11.8.2 FINANCIAL OVERVIEW 98
    • 11.8.3 PRODUCTS/SERVICES OFFERED 98
    • 11.8.4 KEY DEVELOPMENTS 99
    • 11.8.5 SWOT ANALYSIS 99
    • 11.8.6 KEY STRATEGIES 99

  • 11.9 SIEMENS 100
    • 11.9.1 COMPANY OVERVIEW 100
    • 11.9.2 FINANCIAL OVERVIEW 101
    • 11.9.3 PRODUCTS/SERVICES OFFERED 101
    • 11.9.4 KEY DEVELOPMENTS 102
    • 11.9.5 SWOT ANALYSIS 102
    • 11.9.6 KEY STRATEGIES 102
  • 11.10 THERMO FISHER SCIENTIFIC INC. 103
    • 11.10.1 COMPANY OVERVIEW 103
    • 11.10.2 FINANCIAL OVERVIEW 104
    • 11.10.3 PRODUCTS/SERVICES OFFERED 105
    • 11.10.4 KEY DEVELOPMENTS 105
    • 11.10.5 SWOT ANALYSIS 106
    • 11.10.6 KEY STRATEGIES 106
  • 11.11 BIO-RAD LABORATORIES, INC. 107
    • 11.11.1 COMPANY OVERVIEW 107
    • 11.11.2 FINANCIAL OVERVIEW 108
    • 11.11.3 PRODUCTS/SERVICES OFFERED 108
    • 11.11.4 KEY DEVELOPMENTS 108
    • 11.11.5 SWOT ANALYSIS 109
    • 11.11.6 KEY STRATEGIES 109
  • 11.12 DANAHER CORPORATION 110
    • 11.12.1 COMPANY OVERVIEW 110
    • 11.12.2 FINANCIAL OVERVIEW 111
    • 11.12.3 PRODUCTS/SERVICES OFFERED 111
    • 11.12.4 KEY DEVELOPMENTS 112
    • 11.12.5 SWOT ANALYSIS 112
    • 11.12.6 KEY STRATEGIES 112
  • 11.13 BIOMERIEUX SA 113
    • 11.13.1 COMPANY OVERVIEW 113
    • 11.13.2 FINANCIAL OVERVIEW 114
    • 11.13.3 PRODUCTS/SERVICES OFFERED 115
    • 11.13.4 KEY DEVELOPMENTS 115
    • 11.13.5 SWOT ANALYSIS 116
    • 11.13.6 KEY STRATEGIES 116

12 APPENDIX 117

  • 12.1 REFERENCES 117
  • 12.2 RELATED REPORTS 117

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19
  • TABLE 3 GLOBAL CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 33
  • TABLE 4 GLOBAL CARDIAC BIOMARKERS MARKET FOR TROPONINS (T AND I), BY REGION, 2017-2027(USD MILLION) 33
  • TABLE 5 GLOBAL CARDIAC BIOMARKERS MARKET FOR MYOCARDIAL MUSCLE CREATINE KINASE (CK-MB), BY REGION, 2017-2027 (USD MILLION) 34
  • TABLE 6 GLOBAL CARDIAC BIOMARKERS MARKET FOR MYOGLOBIN, BY REGION, 2017-2027 (USD MILLION) 34
  • TABLE 7 GLOBAL CARDIAC BIOMARKERS MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNPS) OR NT-PROBNP, BY REGION, 2017-2027 (USD MILLION) 35
  • TABLE 8 GLOBAL CARDIAC BIOMARKERS MARKET FOR ISCHEMIA MODIFIED ALBUMIN (IMA), BY REGION, 2017-2027 (USD MILLION) 35
  • TABLE 9 GLOBAL CARDIAC BIOMARKERS MARKET FOR ALT/AST, BY REGION, 2017-2027 (USD MILLION) 36
  • TABLE 10 GLOBAL CARDIAC BIOMARKERS MARKET FOR OTHERS, BY REGION, 2017-2027 (USD MILLION) 36
  • TABLE 11 GLOBAL CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 38
  • TABLE 12 GLOBAL CARDIAC BIOMARKERS MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2017-2027 (USD MILLION) 38
  • TABLE 13 GLOBAL CARDIAC BIOMARKERS MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2017-2027 (USD MILLION) 39
  • TABLE 14 GLOBAL CARDIAC BIOMARKERS MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2017-2027 (USD MILLION) 39
  • TABLE 15 GLOBAL CARDIAC BIOMARKERS MARKET FOR ATHEROSCLEROSIS, BY REGION, 2017-2027(USD MILLION) 40
  • TABLE 16 GLOBAL CARDIAC BIOMARKERS MARKET FOR OTHERS, BY REGION, 2017-2027 (USD MILLION) 40
  • TABLE 17 GLOBAL CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 41
  • TABLE 18 GLOBAL CARDIAC BIOMARKERS MARKET FOR POINT OF CARE TESTING, BY REGION, 2017-2027 (USD MILLION) 42
  • TABLE 19 GLOBAL CARDIAC BIOMARKERS MARKET FOR LABORATORY TESTING, BY REGION, 2017-2027 (USD MILLION) 42
  • TABLE 20 GLOBAL CARDIAC BIOMARKERS MARKET, BY REGION, 2017-2027 (USD MILLION) 44
  • TABLE 21 AMERICAS CARDIAC BIOMARKERS MARKET, BY REGION, 2017-2027 (USD MILLION) 45
  • TABLE 22 AMERICAS CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 45
  • TABLE 23 AMERICAS CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 46
  • TABLE 24 AMERICAS CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 46
  • TABLE 25 NORTH AMERICA CARDIAC BIOMARKERS MARKET, BY COUNTRY, 2017-2027 (USD MILLION) 47
  • TABLE 26 NORTH AMERICA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 47
  • TABLE 27 NORTH AMERICA CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 48
  • TABLE 28 NORTH AMERICA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027(USD MILLION) 48
  • TABLE 29 US CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 49
  • TABLE 30 US CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 49
  • TABLE 31 US CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 50
  • TABLE 32 CANADA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 51
  • TABLE 33 CANADA CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 51
  • TABLE 34 CANADA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 51
  • TABLE 35 LATIN AMERICA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 52
  • TABLE 36 LATIN AMERICA CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 52
  • TABLE 37 LATIN AMERICA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 52
  • TABLE 38 EUROPE CARDIAC BIOMARKERS MARKET, BY REGION, 2017-2027 (USD MILLION) 53
  • TABLE 39 EUROPE CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 53
  • TABLE 40 EUROPE CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 54
  • TABLE 41 EUROPE CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 54
  • TABLE 42 WESTERN EUROPE CARDIAC BIOMARKERS MARKET, BY COUNTRY, 2017-2027 (USD MILLION) 55
  • TABLE 43 WESTERN EUROPE CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 56
  • TABLE 44 WESTERN EUROPE CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 56
  • TABLE 45 WESTERN EUROPE CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 56
  • TABLE 46 GERMANY CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 57
  • TABLE 47 GERMANY CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 57
  • TABLE 48 GERMANY CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 57
  • TABLE 49 UK CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 58
  • TABLE 50 UK CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 58
  • TABLE 51 UK CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 58
  • TABLE 52 FRANCE CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 59
  • TABLE 53 FRANCE CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 59
  • TABLE 54 FRANCE CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 59
  • TABLE 55 ITALY CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 60
  • TABLE 56 ITALY CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 60
  • TABLE 57 ITALY CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 60
  • TABLE 58 SPAIN CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 61
  • TABLE 59 SPAIN CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 61
  • TABLE 60 SPAIN CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 61
  • TABLE 61 REST OF WESTERN EUROPE CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 62
  • TABLE 62 REST OF WESTERN EUROPE CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 62
  • TABLE 63 REST OF WESTERN EUROPE CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 62
  • TABLE 64 EASTERN EUROPE CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 63
  • TABLE 65 EASTERN EUROPE CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 63
  • TABLE 66 EASTERN EUROPE CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 63
  • TABLE 67 ASIA-PACIFIC CARDIAC BIOMARKERS MARKET, BY COUNTRY, 2017-2027 (USD MILLION) 64
  • TABLE 68 ASIA-PACIFIC CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 65
  • TABLE 69 ASIA-PACIFIC CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 65
  • TABLE 70 ASIA-PACIFIC CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 65
  • TABLE 71 CHINA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 66
  • TABLE 72 CHINA CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 66
  • TABLE 73 CHINA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 66
  • TABLE 74 INDIA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 67
  • TABLE 75 INDIA CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 67
  • TABLE 76 INDIA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 67
  • TABLE 77 JAPAN CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 68
  • TABLE 78 JAPAN CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 68
  • TABLE 79 JAPAN CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 68
  • TABLE 80 SOUTH KOREA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 69
  • TABLE 81 SOUTH KOREA CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 69
  • TABLE 82 SOUTH KOREA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 69
  • TABLE 83 AUSTRALIA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 70
  • TABLE 84 AUSTRALIA CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 70
  • TABLE 85 AUSTRALIA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 70
  • TABLE 86 REST OF ASIA-PACIFIC CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 71
  • TABLE 87 REST OF ASIA-PACIFIC CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 71
  • TABLE 88 REST OF ASIA-PACIFIC CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 71
  • TABLE 89 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET, BY REGION, 2017-2027 (USD MILLION) 72
  • TABLE 90 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 73
  • TABLE 91 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 73
  • TABLE 92 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 73
  • TABLE 93 MIDDLE EAST CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 74
  • TABLE 94 MIDDLE EAST CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 74
  • TABLE 95 MIDDLE EAST CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 74
  • TABLE 96 AFRICA CARDIAC BIOMARKERS MARKET, BY TYPE, 2017-2027 (USD MILLION) 75
  • TABLE 97 AFRICA CARDIAC BIOMARKERS, BY APPLICATION, 2017-2027 (USD MILLION) 75
  • TABLE 98 AFRICA CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2017-2027 (USD MILLION) 75
  • TABLE 99 MAJOR PLAYERS IN THE GLOBAL CARDIAC BIOMARKERS MARKET 77
  • TABLE 100 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 79
  • TABLE 101 QUIDEL CORPORATION: PRODUCTS/SERVICES OFFERED 82
  • TABLE 102 F. HOFFMAN LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 84
  • TABLE 103 RANDOX LABORATORIES LTD: PRODUCTS/SERVICES OFFERED 86
  • TABLE 104 TRIVITRON HEALTHCARE: PRODUCTS/SERVICES OFFERED 88
  • TABLE 105 F. HOFFMAN LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 92
  • TABLE 106 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS/SERVICES OFFERED 95
  • TABLE 107 ABBOTT LABORATORIES: PRODUCTS/SERVICES OFFERED 98
  • TABLE 108 SIEMENS: PRODUCTS/SERVICES OFFERED 101
  • TABLE 109 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 105
  • TABLE 110 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 108
  • TABLE 111 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 111
  • TABLE 112 BIOMERIEUX SA: PRODUCTS/SERVICES OFFERED 115  

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS 14
  • FIGURE 2 GLOBAL CARDIAC BIOMARKERS MARKET STRUCTURE 15
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 21
  • FIGURE 4 MARKET DYNAMICS: CARDIAC BIOMARKER MARKET 24
  • FIGURE 5 DRIVERS: IMPACT ANALYSIS 25
  • FIGURE 6 RESTRAINTS: IMPACT ANALYSIS 26
  • FIGURE 7 VALUE CHAIN: CARDIAC BIOMARKERS MARKET 27
  • FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: CARDIAC BIOMARKERS MARKET 29
  • FIGURE 9 GLOBAL CARDIAC BIOMARKERS MARKET, BY TYPE, 2019 & 2027 (USD MILLION) 32
  • FIGURE 10 GLOBAL CARDIAC BIOMARKERS MARKET, BY APPLICATION, 2019 & 2027 (USD MILLION) 37
  • FIGURE 11 GLOBAL CARDIAC BIOMARKERS MARKET, BY LOCATION OF TESTING, 2019 & 2027 (USD MILLION) 41
  • FIGURE 12 GLOBAL CARDIAC BIOMARKERS MARKET, BY REGION 2019 & 2027 (USD MILLION) 43
  • FIGURE 13 GLOBAL CARDIAC BIOMARKERS MARKET SHARE, BY REGION 2019 (%) 44
  • FIGURE 14 AMERICAS CARDIAC BIOMARKERS MARKET SHARE, BY REGION 2019 (%) 45
  • FIGURE 15 WESTERN EUROPE CARDIAC BIOMARKERS MARKET SHARE, BY COUNTRY 2019 (%) 55
  • FIGURE 16 ASIA-PACIFIC CARDIAC BIOMARKERS MARKET SHARE, BY COUNTRY 2019 (%) 64
  • FIGURE 17 MIDDLE EAST & AFRICA CARDIAC BIOMARKERS MARKET SHARE, BY REGION 2019 (%) 72
  • FIGURE 18 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 79
  • FIGURE 19 NOVARTIS AG: SWOT ANALYSIS 80
  • FIGURE 20 QUIDEL CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 82
  • FIGURE 21 QUIDEL CORPORATION: SWOT ANALYSIS 83
  • FIGURE 22 ACS BIOMARKER B.V.: SWOT ANALYSIS 85
  • FIGURE 23 RANDOX LABORATORIES LTD: SWOT ANALYSIS 87
  • FIGURE 24 TRIVITRON HEALTHCARE: SWOT ANALYSIS 89
  • FIGURE 25 F. HOFFMAN LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 91
  • FIGURE 26 F. HOFFMAN LA ROCHE LTD: SWOT ANALYSIS 92
  • FIGURE 27 JOHNSON & JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT 95
  • FIGURE 28 JOHNSON & JOHNSON SERVICES INC.: SWOT ANALYSIS 96
  • FIGURE 29 ABBOTT LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT 98
  • FIGURE 30 ABBOTT LABORATORIES: SWOT ANALYSIS 99
  • FIGURE 31 SIEMENS: FINANCIAL OVERVIEW SNAPSHOT 101
  • FIGURE 32 SIEMENS: SWOT ANALYSIS 102
  • FIGURE 33 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 104
  • FIGURE 34 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 106
  • FIGURE 35 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 108
  • FIGURE 36 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS 109
  • FIGURE 37 DANAHER CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 111
  • FIGURE 38 DANAHER CORPORATION: SWOT ANALYSIS 112
  • FIGURE 39 BIOMERIEUX SA: FINANCIAL OVERVIEW SNAPSHOT 114
  • FIGURE 40 BIOMERIEUX SA: SWOT ANALYSIS 116